Il y a eu 50 transactions d'initiés récentes enregistrées pour Madrigal Pharmaceuticals, Inc. (MDGL), dont 20 achats et 27 ventes. Le total des achats d'initiés s'élève à $37.6M et le total des ventes d'initiés à $8.97M.
Les initiés notables ayant une activité récente comprennent Taub Rebecca, Sibold William John, Dier Mardi. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — MDGL
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-06 |
Taub Rebecca |
Director |
Vente Informative |
491 |
$431.94 |
$212.08K |
452,213 |
| 2026-03-06 |
Sibold William John |
President and CEO |
Vente Informative |
1,663 |
$431.94 |
$718.32K |
161,829 |
| 2026-03-06 |
Dier Mardi |
EVP and CFO |
Vente Informative |
40 |
$437.65 |
$17.51K |
12,490 |
| 2026-03-06 |
Huntsman Carole |
Chief Commercial Officer |
Vente Informative |
419 |
$431.94 |
$180.98K |
12,692 |
| 2026-03-06 |
Kelley Shannon T |
General Counsel |
Vente Informative |
360 |
$431.94 |
$155.5K |
12,138 |
| 2026-03-04 |
Sibold William John |
President and CEO |
Attribution de RSU |
18,743 |
$434.80 |
$8.15M |
18,743 |
| 2026-03-04 |
Dier Mardi |
EVP and CFO |
Attribution de RSU |
6,519 |
$434.80 |
$2.83M |
6,519 |
| 2026-03-04 |
Soergel David |
Chief Medical Officer |
Attribution de RSU |
5,467 |
$434.80 |
$2.38M |
5,467 |
| 2026-03-04 |
Huntsman Carole |
Chief Commercial Officer |
Attribution de RSU |
4,986 |
$434.80 |
$2.17M |
4,986 |
| 2026-03-04 |
Kelley Shannon T |
General Counsel |
Attribution de RSU |
5,022 |
$434.80 |
$2.18M |
5,022 |
| 2026-03-02 |
Dier Mardi |
EVP and CFO |
Vente Informative |
1,183 |
$427.21 |
$505.39K |
9,257 |
| 2026-02-23 |
Levy Richard S |
Director |
Exercice d'Options (Vente) |
2,500 |
$7.36 |
$18.4K |
- |
| 2026-01-26 |
Taub Rebecca |
Director |
Vente Informative |
647 |
$492.42 |
$318.6K |
452,704 |
| 2026-01-26 |
Levy Richard S |
Director |
Exercice d'Options (Vente) |
4,000 |
$16.46 |
$65.84K |
- |
| 2026-01-26 |
Sibold William John |
President and CEO |
Vente Informative |
1,577 |
$492.42 |
$776.55K |
148,497 |
| 2026-01-26 |
Huntsman Carole |
Chief Commercial Officer |
Vente Informative |
570 |
$494.59 |
$281.92K |
9,122 |
| 2026-01-20 |
Taub Rebecca |
Director |
Vente Informative |
2,238 |
$490.77 |
$1.1M |
453,351 |
| 2026-01-20 |
Kelley Shannon T |
General Counsel |
Vente Informative |
429 |
$501.40 |
$215.1K |
8,481 |
| 2026-01-15 |
Thakkar Rita |
Chief Accounting Officer |
Attribution de RSU |
1,826 |
$495.88 |
$905.48K |
1,826 |
| 2026-01-12 |
Thakkar Rita |
Officer |
Inconnu |
- |
- |
- |
- |
| 2026-01-09 |
Friedman Paul A |
Director |
Exercice d'Options (Vente) |
24,520 |
$15.80 |
$387.42K |
280 |
| 2026-01-09 |
Taub Rebecca |
Director |
Vente Informative |
271 |
$534.18 |
$144.76K |
457,242 |
| 2025-06-20 |
Bate Kenneth |
Director |
Attribution de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Friedman Paul A |
Director |
Attribution de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Baker Bros. Advisors Lp |
Director |
Attribution de RSU |
2,580 |
$285.73 |
$737.18K |
2,580 |
| 2025-06-20 |
Fouse Jacqualyn A |
Director |
Attribution de RSU |
366 |
$285.73 |
$104.58K |
366 |
| 2025-06-20 |
Levy Richard S |
Director |
Attribution de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Daly James M |
Director |
Attribution de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-05-15 |
Soergel David |
Chief Medical Officer |
Attribution de RSU |
7,545 |
- |
- |
7,545 |
| 2025-04-21 |
Soergel David |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-03-13 |
Craves Fred B |
Director |
Exercice d'Options (Vente) |
7,742 |
$65.06 |
$503.69K |
- |
| 2025-03-12 |
Craves Fred B |
Director |
Exercice d'Options (Vente) |
6,000 |
$111.06 |
$666.36K |
- |
| 2025-03-10 |
Fouse Jacqualyn A |
Director |
Inconnu |
- |
- |
- |
- |
| 2025-03-10 |
Fouse Jacqualyn A |
Director |
Attribution de RSU |
894 |
- |
- |
894 |
| 2025-03-10 |
Dier Mardi |
SVP and CFO |
Vente Informative |
258 |
$323.04 |
$83.34K |
10,440 |
| 2025-03-05 |
Taub Rebecca |
Pres., R&d, and CMO |
Attribution de RSU |
7,381 |
$347.28 |
$2.56M |
7,381 |
| 2025-03-05 |
Sibold William John |
President and CEO |
Attribution de RSU |
22,009 |
$347.28 |
$7.64M |
22,009 |
| 2025-03-05 |
Dier Mardi |
SVP and CFO |
Attribution de RSU |
6,374 |
$347.28 |
$2.21M |
6,374 |
| 2025-03-05 |
Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
Attribution de RSU |
1,157 |
$347.28 |
$401.8K |
1,157 |
| 2025-03-05 |
Huntsman Carole |
Chief Commercial Officer |
Attribution de RSU |
5,703 |
$347.28 |
$1.98M |
5,703 |
| 2025-03-05 |
Kelley Shannon T |
General Counsel |
Attribution de RSU |
5,368 |
$347.28 |
$1.86M |
5,368 |
| 2025-03-03 |
Dier Mardi |
SVP and CFO |
Vente Informative |
774 |
$323.54 |
$250.42K |
6,914 |
| 2025-03-03 |
Huntsman Carole |
Chief Commercial Officer |
Vente Informative |
563 |
$335.00 |
$188.61K |
8,604 |
| 2025-03-03 |
Kelley Shannon T |
General Counsel |
Vente Informative |
415 |
$335.00 |
$139.03K |
7,290 |
| 2025-02-28 |
Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
Vente Informative |
175 |
$341.55 |
$59.77K |
3,728 |
| 2025-02-27 |
Bate Kenneth |
Director |
Exercice d'Options (Vente) |
9,470 |
$65.06 |
$616.12K |
- |
| 2025-02-27 |
Sibold William John |
President and CEO |
Exercice d'Options (Vente) |
50,000 |
- |
- |
- |
| 2025-02-27 |
Daly James M |
Director |
Exercice d'Options (Vente) |
9,470 |
$65.06 |
$616.12K |
- |
| 2025-01-24 |
Taub Rebecca |
Pres., R&d, and CMO |
Vente Informative |
648 |
$335.24 |
$217.24K |
456,662 |
| 2025-01-24 |
Sibold William John |
President and CEO |
Vente Informative |
1,584 |
$335.24 |
$531.02K |
54,303 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
